Bremelanotide vs BI 456906
Head-to-head comparison of Bremelanotide (Bremelanotide (PT-141), cyclic melanocortin receptor agonist) and BI 456906 (BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Bremelanotide | BI 456906 |
|---|---|---|
| Category | Sexual Health | Weight Management |
| Full Name | Bremelanotide (PT-141), cyclic melanocortin receptor agonist | BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | 1025.2 Da | N/A |
| Half-Life | about 2.7 h | Approximately 1 week |
| Amino Acids | 7 | N/A |
| Typical Dose | 1.75 mg | Trial-dependent; weekly SC dosing |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 200 | 10 |
| Research Status | Clinical | Clinical |
Bremelanotide Benefits
- ✓increases sexual desire
- ✓supports arousal
- ✓may improve erectile response
- ✓on-demand use
BI 456906 Benefits
- ✓weight reduction
- ✓improved glucose control
- ✓lower liver-fat burden
- ✓enhanced satiety
Bremelanotide Dosing
1.75 mg subcutaneous PRN|administer about 45 minutes before activity|max 1 dose per 24 hours
BI 456906 Dosing
once-weekly subcutaneous injection|stepwise titration|ongoing maintenance phase
Bremelanotide Side Effects
- ⚠nausea
- ⚠flushing
- ⚠headache
- ⚠transient blood pressure increase
BI 456906 Side Effects
- ⚠nausea
- ⚠abdominal discomfort
- ⚠diarrhea
Research Overview
Bremelanotide
Human studies and approval data support meaningful effects on sexual desire in women, with a central mechanism involving melanocortin signaling. It is one of the most clinically relevant peptides in this category and is commonly used as the reference compound for PT-141-type research.
BI 456906
Preclinical and early clinical research support meaningful metabolic effects with a tolerable safety profile. It remains investigational and is not commercially available.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.